Jeffrey N Bruce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5671186/publications.pdf

Version: 2024-02-01

76326 82547 6,330 146 40 72 citations h-index g-index papers 152 152 152 9183 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	BOLD asynchrony elucidates tumor burden in IDH-mutated gliomas. Neuro-Oncology, 2022, 24, 78-87.	1.2	9
2	Adenocarcinoma Arising in a Yolk Sac Tumor of the Pineal Gland. Journal of Neuropathology and Experimental Neurology, 2022, 81, 291-295.	1.7	0
3	Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutations. Acta Neuropathologica Communications, 2022, 10, 64.	5.2	1
4	DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Neuro-Oncology, 2022, 24, i35-i35.	1.2	3
5	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 2022, 185, 2591-2608.e30.	28.9	62
6	Gonadotroph tumours with a low SF $\hat{a}\in \mathbb{I}$ labelling index are more likely to recur and are associated with enrichment of the PI3K $\hat{a}\in A$ KT pathway. Neuropathology and Applied Neurobiology, 2021, 47, 415-427.	3.2	8
7	Therapeutic Outcomes of Spheno-orbital Meningiomas and Factors Influencing Recurrence over a 32-Year Period., 2021, 82, .		O
8	Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly. Journal of the Endocrine Society, 2021, 5, bvab004.	0.2	16
9	ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	O
10	Focused ultrasound mediated blood–brain barrier opening is safe and feasible in a murine pontine glioma model. Scientific Reports, 2021, 11, 6521.	3.3	41
11	ETMM-05. LACTIC ACID FACILITATES GLIOBLASTOMA GROWTH THROUGH MODULATION OF THE EPIGENOME. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	O
12	Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. Journal of Neurosurgery, 2021, 134, 1357-1367.	1.6	31
13	Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq. Genome Medicine, 2021, 13, 82.	8.2	43
14	Rationale and Clinical Implications of Fluorescein-Guided Supramarginal Resection in Newly Diagnosed High-Grade Glioma. Frontiers in Oncology, 2021, 11, 666734.	2.8	22
15	Asynchrony in Peritumoral Resting-State Blood Oxygen Level–Dependent fMRI Predicts Meningioma Grade and Invasion. American Journal of Neuroradiology, 2021, 42, 1293-1298.	2.4	2
16	Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker. Genome Medicine, 2021, 13, 88.	8.2	57
17	Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 110, 539-550.	0.8	44
18	HGC-40. FOCUSED ULTRASOUND ENHANCES ETOPOSIDE DELIVERY IN A MURINE PONTINE GLIOMA MODEL. Neuro-Oncology, 2021, 23, i25-i26.	1.2	0

#	Article	IF	Citations
19	Right occipital transtentorial approach for a pineal malignant germ cell tumor. Neurosurgical Focus Video, 2021, 5, V3.	0.3	0
20	OTEH-6. Algorithmic approach to characterize post-treatment recurrent glioma using RNA sequencing and quantitative histopathology. Neuro-Oncology Advances, 2021, 3, ii11-ii11.	0.7	0
21	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nature Communications, 2021, 12, 5203.	12.8	38
22	Rosette-Forming Glioneuronal Tumor in the Pineal Region: A Series of 6 Cases and Literature Review. Journal of Neuropathology and Experimental Neurology, 2021, 80, 933-943.	1.7	7
23	Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience. Pharmaceutics, 2021, 13, 39.	4.5	9
24	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39
25	Frameless Stereotactic Radiosurgery on the Gamma Knife Icon: Early Experience From 100 Patients. Neurosurgery, 2020, 86, 509-516.	1.1	31
26	MET Inhibition Elicits PGC1 \hat{l}_{\pm} -Dependent Metabolic Reprogramming in Glioblastoma. Cancer Research, 2020, 80, 30-43.	0.9	35
27	Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nature Medicine, 2020, 26, 52-58.	30.7	413
28	Patterns of seizure prophylaxis after oncologic neurosurgery. Journal of Neuro-Oncology, 2020, 146, 171-180.	2.9	21
29	Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers. ACS Chemical Biology, 2020, 15, 469-484.	3.4	280
30	Current Management of Craniopharyngiomas. Current Treatment Options in Allergy, 2020, 7, 347-355.	2.2	0
31	Gross Total Versus Subtotal Surgical Resection in the Management of Craniopharyngiomas. Allergy and Rhinology, 2020, 11, 215265672096415.	1.6	21
32	Integrating single-cell RNA-seq and imaging with SCOPE-seq2. Scientific Reports, 2020, 10, 19482.	3.3	16
33	Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study. Journal of the Endocrine Society, 2020, 4, bvaa021.	0.2	20
34	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. British Journal of Neurosurgery, 2020, 34, 690-696.	0.8	10
35	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. Journal of Clinical Investigation, 2020, 130, 3699-3716.	8.2	104
36	Fluorescein-guided resection of gliomas. Journal of Neurosurgical Sciences, 2020, 63, 648-655.	0.6	9

#	Article	IF	CITATIONS
37	Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model. Journal of Neurosurgery, 2020, 133, 614-623.	1.6	17
38	Endoscopic Petrous Apex Surgery: The Utilization of Frontal Sinus Instrumentation. Journal of Craniofacial Surgery, 2020, 31, 2317-2319.	0.7	0
39	DDEL-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2020, 22, iii284-iii285.	1.2	O
40	DDEL-13. FOCUSED ULTRASOUND MEDIATED BLOOD BRAIN BARRIER DISRUPTION IN A MURINE MODEL OF PONTINE GLIOMA: A SAFETY AND FEASIBILITY STUDY. Neuro-Oncology, 2020, 22, iii286-iii286.	1.2	0
41	Novel Pineal Germinoma Model Demonstrates Sensitivity to MTOR Inhibition. , 2020, 81, .		0
42	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii47-ii48.	1.2	0
43	TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii220-ii220.	1.2	0
44	EPCO-16. LACTIC ACID IS AN EPIGENETIC METABOLITE THAT DRIVES GLIOBLASTOMA SURVIVAL AND GROWTH. Neuro-Oncology, 2020, 22, ii72-ii72.	1.2	0
45	EPCO-07. LEVERAGING TRANSCRIPTOME SEQUENCING AND MATHEMATICAL MODELING TO INVESTIGATE GLIOBLASTOMA-MACROPHAGE INTERACTIONS. Neuro-Oncology, 2020, 22, ii70-ii70.	1.2	0
46	NIMG-67. DISAPPEARING DOTS – TRANSIENT LATE ENHANCING LESIONS YEARS AFTER BRAIN RADIOTHERAPY. Neuro-Oncology, 2020, 22, ii163-ii163.	1.2	0
47	Extent of resection and survival for oligodendroglioma: a U.S. population-based study. Journal of Neuro-Oncology, 2019, 144, 591-601.	2.9	45
48	RADI-14. FRAMELESS STEREOTACTIC RADIOSURGERY ON THE GAMMA KNIFE ICON: EARLY EXPERIENCE FROM 42 PATIENTS WITH BRAIN METASTASES. Neuro-Oncology Advances, 2019, 1, i24-i24.	0.7	0
49	Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system. Journal of Neuro-Oncology, 2019, 143, 457-464.	2.9	14
50	Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics, 2019, 12, 56.	1.5	7
51	Plasma Agouti-Related Protein and Cortisol Levels in Cushing Disease: Evidence for the Regulation of Agouti-Related Protein by Glucocorticoids in Humans. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 961-969.	3.6	9
52	<i>De novo</i> gene signature identification from singleâ€cell <scp>RNA</scp> â€seq with hierarchical Poisson factorization. Molecular Systems Biology, 2019, 15, e8557.	7.2	78
53	Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases. Journal of Neuro-Oncology, 2019, 143, 145-155.	2.9	14
54	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569

#	Article	IF	CITATIONS
55	NIMG-61. USING MACHINE LEARNING TO BUILD RADIOMICS MODELS THAT DISTINGUISH REGIONS OF GLIOBLASTOMA RECURRENCE VS TUMOR PROGRESSION ON MRI. Neuro-Oncology, 2019, 21, vi175-vi175.	1.2	O
56	TMOD-14. RADIOGRAPHIC, STIMULATED RAMAN HISTOLOGIC, AND MULTIPLEXED RNA-SEQUENCING ANALYSIS OF POST-TREATMENT RECURRENT HIGH-GRADE GLIOMAS. Neuro-Oncology, 2019, 21, vi265-vi265.	1.2	0
57	Magnetic Resonance Imaging-Based Screening for Asymptomatic Brain Tumors: A Review. Oncologist, 2019, 24, 375-384.	3.7	22
58	Craniotomy and Survival for Primary Central Nervous System Lymphoma. Neurosurgery, 2019, 84, 935-944.	1.1	46
59	Review of clinical trials in intraoperative molecular imaging during cancer surgery. Journal of Biomedical Optics, 2019, 24, 1.	2.6	40
60	The Annual Neurosurgery Charity Softball Tournament: 15th Anniversary Commemorative Article. The creation, development, and establishment of a neurosurgical tradition. Journal of Neurosurgery, 2018, 128, 1605-1611.	1.6	2
61	Capturing Quality: The Challenge for High-Volume Academic Medical Centers. Mayo Clinic Proceedings, 2018, 93, 4-6.	3.0	3
62	Local Glioma Cells Are Associated with Vascular Dysregulation. American Journal of Neuroradiology, 2018, 39, 507-514.	2.4	16
63	Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation. Radiology, 2018, 287, 965-972.	7.3	15
64	Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. CNS Oncology, 2018, 7, 25-34.	3.0	9
65	Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. Journal of Neuro-Oncology, 2018, 138, 173-182.	2.9	59
66	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. Journal of Neuro-Oncology, 2018, 137, 303-311.	2.9	43
67	Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas. Neurosurgery, 2018, 82, 719-727.	1.1	38
68	Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease. Journal of Neuro-Oncology, 2018, 136, 281-287.	2.9	6
69	The modified frailty index and 30-day adverse events in oncologic neurosurgery. Journal of Neuro-Oncology, 2018, 136, 197-206.	2.9	76
70	Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. Neurosurgery, 2018, 83, 263-269.	1.1	14
71	Letter: Surgical Decision Making From Image-Based Biophysical Modeling of Glioblastoma: Not Ready for Primetime. Neurosurgery, 2018, 82, E17-E18.	1.1	2
72	Single-cell transcriptome analysis of lineage diversity in high-grade glioma. Genome Medicine, 2018, 10, 57.	8.2	162

#	Article	lF	Citations
73	Pineal region glioblastomas display features of diffuse midline and non-midline gliomas. Journal of Neuro-Oncology, 2018, 140, 63-73.	2.9	17
74	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. Neurosurgery, 2017, 80, 590-601.	1.1	34
7 5	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. Journal of Neuro-Oncology, 2017, 132, 189-197.	2.9	25
76	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	7.0	78
77	A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies. American Journal of Neuroradiology, 2017, 38, 890-898.	2.4	90
78	Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas. Journal of Neuro-Oncology, 2017, 133, 77-85.	2.9	12
79	Extent of Resection in Glioma–A Review of the Cutting Edge. World Neurosurgery, 2017, 103, 538-549.	1.3	134
80	Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. Journal of Neuro-Oncology, 2017, 133, 409-417.	2.9	14
81	Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Research, 2017, 77, 3513-3526.	0.9	56
82	Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nature Communications, 2017, 8, 1067.	12.8	91
83	Targeting brain tumors by intra-arterial delivery of cell-penetrating peptides: a novel approach for primary and metastatic brain malignancy. Journal of Neuro-Oncology, 2017, 135, 497-506.	2.9	11
84	Subependymomas Are Low-Grade Heterogeneous Glial Neoplasms Defined by Subventricular Zone Lineage Markers. World Neurosurgery, 2017, 107, 451-463.	1.3	28
85	Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development. Journal of Neuro-Oncology, 2017, 134, 453-463.	2.9	16
86	Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. Journal of Neurosurgery, 2017, 127, 111-122.	1.6	122
87	Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival. Tomography, 2017, 3, 131-137.	1.8	15
88	Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2016, 7, 12791-12805.	1.8	35
89	IMST-41. PARALLEL PROFILING OF MUTATIONAL LANDSCAPE, GENE EXPRESSION, AND T-CELL RECEPTOR REPERTOIRES IN SUBEPENDYMOMA REVEALS IMMUNOPHENOTYPIC HETEROGENEITY. Neuro-Oncology, 2016, 18, vi95-vi96.	1.2	0
90	NIMG-57. BOLD fMRI REFLECTS THE LOCAL PRESENCE OF GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi137-vi137.	1,2	0

#	Article	IF	CITATIONS
91	Microsurgical resection of pineal region tumors. Journal of Neuro-Oncology, 2016, 130, 351-366.	2.9	63
92	Liposome size and charge optimization for intraarterial delivery to gliomas. Drug Delivery and Translational Research, 2016, 6, 225-233.	5.8	31
93	A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Clinical Cancer Research, 2016, 22, 4698-4711.	7.0	63
94	Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. Journal of Neuro-Oncology, 2016, 130, 449-454.	2.9	10
95	Computational pharmacokinetic rationale for intra-arterial delivery to the brain. Drug Delivery and Translational Research, 2016, 6, 622-629.	5.8	9
96	Cationizable lipid micelles as vehicles for intraarterial glioma treatment. Journal of Neuro-Oncology, 2016, 128, 21-28.	2.9	12
97	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. World Neurosurgery, 2016, 89, 362-367.	1.3	98
98	Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3529-37.	7.1	103
99	Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Practical Radiation Oncology, 2016, 6, 306-314.	2.1	17
100	Venous air embolus during scalp incision. Journal of Clinical Neuroscience, 2016, 28, 170-171.	1.5	3
101	A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma. World Neurosurgery, 2016, 88, 260-269.	1.3	7
102	An ID2-dependent mechanism for VHL inactivation in cancer. Nature, 2016, 529, 172-177.	27.8	108
103	Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery. Journal of Neuro-Oncology, 2016, 127, 103-110.	2.9	16
104	Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget, 2016, 7, 33512-33528.	1.8	47
105	Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment. Journal of Drug Delivery, 2015, 2015, 1-15.	2.5	19
106	TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2015, 6, 36456-36471.	1.8	57
107	Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. World Neurosurgery, 2015, 84, 1084-1089.	1.3	112
108	Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2946-2955.	3.6	56

#	Article	IF	Citations
109	Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma. World Neurosurgery, 2015, 84, 163-172.	1.3	4
110	Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics. CNS Oncology, 2015, 4, 225-234.	3.0	24
111	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?. Neuro-Oncology, 2015, 17, 1022-1028.	1.2	39
112	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. World Neurosurgery, 2015, 84, 913-919.	1.3	44
113	IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition. Pituitary, 2015, 18, 808-819.	2.9	44
114	Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. Journal of Neuro-Oncology, 2015, 124, 507-514.	2.9	33
115	Intraarterial drug delivery for glioblastoma mutiforme. Journal of Neuro-Oncology, 2015, 124, 333-343.	2.9	27
116	Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> Oncotarget, 2015, 6, 14507-14521.	1.8	45
117	Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase lb trial evaluating topotecan by convection-enhanced delivery. Neuro-Oncology Practice, 2014, 1, 94-100.	1.6	3
118	Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro-Oncology, 2014, 16, 1210-1219.	1.2	34
119	Prospective Study of Surgical Treatment of Acromegaly: Effects on Ghrelin, Weight, Adiposity, and Markers of CV Risk. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4124-4132.	3.6	43
120	Neurosurgical oncology: advances in operative technologies and adjuncts. Journal of Neuro-Oncology, 2014, 119, 451-463.	2.9	45
121	MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12550-12555.	7.1	224
122	The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression. Cancer Research, 2014, 74, 1440-1451.	0.9	48
123	Management Paradigms Along a Histologic Spectrum of Pineal Cell Tumors. World Neurosurgery, 2014, 81, 685-687.	1.3	3
124	Real-time hemodynamic response and mitochondrial function changes with intracarotid mannitol injection. Brain Research, 2014, 1549, 42-51.	2.2	8
125	Monocyte-Derived Cells of the Brain and Malignant Gliomas: Translational Implications. World Neurosurgery, 2014, 82, 1015-1016.	1.3	0
126	Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors Journal of Clinical Oncology, 2014, 32, 179-179.	1.6	46

#	Article	IF	CITATIONS
127	Outcomes of Gamma Knife radiosurgery, bimodality, and trimodality treatment regimens for patients with one or multiple brain metastases: The Columbia University Medical Center experience Journal of Clinical Oncology, 2014, 32, e13032-e13032.	1.6	O
128	Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. Journal of Neurosurgery: Pediatrics, 2013, 11, 289-295.	1.3	80
129	Patient-specific biomathematical model to predict benefit of resection in human gliomas Journal of Clinical Oncology, 2013, 31, e13017-e13017.	1.6	0
130	Sitting Position for the Removal of Pineal Region Lesions. World Neurosurgery, 2012, 77, 657-658.	1.3	7
131	Regression of Recurrent Malignant Gliomas With Convection-Enhanced Delivery of Topotecan. Neurosurgery, 2011, 69, 1272-1280.	1.1	133
132	Convection-Enhanced Delivery of Topotecan into a PDGF-Driven Model of Glioblastoma Prolongs Survival and Ablates Both Tumor-Initiating Cells and Recruited Glial Progenitors. Cancer Research, 2011, 71, 3963-3971.	0.9	38
133	Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro-Oncology, 2011, 13, 886-893.	1.2	56
134	Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains underâ€recognized and underâ€diagnosed. Clinical Endocrinology, 2010, 72, 203-208.	2.4	191
135	Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. Journal of Neuro-Oncology, 2009, 95, 377-382.	2.9	68
136	Lower Visceral and Subcutaneous but Higher Intermuscular Adipose Tissue Depots in Patients with Growth Hormone and Insulin-Like Growth Factor I Excess Due to Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2334-2343.	3.6	99
137	Surgical Strategies for Treating Patients with Pineal Region Tumors. Journal of Neuro-Oncology, 2004, 69, 221-236.	2.9	112
138	Preservation of bone flaps in patients with postcraniotomy infections. Journal of Neurosurgery, 2003, 98, 1203-1207.	1.6	74
139	Limitations of the C6/Wistar Rat Intracerebral Glioma Model: Implications for Evaluating Immunotherapy. Neurosurgery, 2000, 47, 993-1000.	1.1	84
140	Intracerebral Clysis in a Rat Glioma Model. Neurosurgery, 2000, 46, 683-691.	1.1	87
141	Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model. Neurosurgery, 2000, 47, 1391-1399.	1.1	84
142	Do Reactive Post-Resection "Injury" Spikes Exist?. Epilepsia, 2000, 41, 1463-1468.	5.1	38
143	Genetic basis of intramedullary spinal cord tumors and therapeutic implications. Journal of Neuro-Oncology, 2000, 47, 239-251.	2.9	26
144	A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. Journal of Neuro-Oncology, 1999, 44, 155-162.	2.9	11

#	Article	IF	CITATIONS
145	Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. Journal of Neurosurgery, 1987, 67, 880-884.	1.6	109
146	Pineal region ganglioglioma: A neoplasm with a bimodal age distribution. , 0, 13, 245.		0